Year: 2025

  • Notification of Major Interest by Alto Invest

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 24 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming its holding in ImmuPharma of 4,870,367 million Ordinary Shares in the capital of the Company, representing 3.99% of the Company’s total voting rights, crossing…

  • PRELIMINARY RESULTS
 for the year ended 31 December 2015

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary  results for the year ended 31 December 2015. Key Highlights: Lupuzor™ Pivotal Phase III clinical trial for Lupuzor™, the Company’s lead programme for the potential breakthrough compound for Lupus, is progressing, in conjunction with Simbec-Orion,…

  • Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2015 has been posted to shareholders. The 2015 Annual Report can be downloaded here The Company’s Annual General Meeting will be held on Thursday 26 May 2016 at…

  • Notification of Preliminary Results. Date: 4 May 2016

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that it will announce its Preliminary results for the year ended 31 December 2015 on Wednesday 4 May 2016. For further information on meetings scheduled around the Preliminary results roadshow or media enquiries, please contact Lisa Baderoon on lisa.baderoon@immupharm.com

  • First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its pivotal Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that…

  • Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received advance assurance from HM Revenue and Customs that it is a qualifying holding for the purposes of the Venture Capital Trust rules (“VCT Advance Assurance”) and a qualifying company for the purposes of the Enterprise Investment…

  • Result of GM

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed. Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: “We are…

  • First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the…

  • First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the…

  • Placing and Subscription Raises £8.3 million

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company“), the specialist drug discovery and development company, is pleased to announce the successful completion of the conditional fund raise, comprising the Placing and Subscription, announced earlier today. The Company has conditionally raised, in aggregate, £8.3 million (before expenses) by way of the placing of 14,901,800 new ordinary shares…